<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="260">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579019</url>
  </required_header>
  <id_info>
    <org_study_id>NV22877</org_study_id>
    <secondary_id>2010-022659-41</secondary_id>
    <nct_id>NCT01579019</nct_id>
  </id_info>
  <brief_title>A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double blind, phase II study will evaluate the efficacy and safety of two
      doses of RO5024048 in combination with ritonavir-boosted danoprevir and Pegasys
      (peginterferon alpha-2a) and Copegus (ribavirin) in patients who failed a prior protease
      inhibitor containing regimen with or without pegylated interferon. Patients will be
      randomized to receive either a 2-week lead-in of RO5024048 (1500 mg or 1000 mg orally twice
      daily) in combination with Pegasys (180 mcg subcutaneously weekly) and Copegus (1000 mg or
      1200 mg orally daily) followed by 24 weeks of therapy with RO5024048 in combination with
      danoprevir (100 mg orally twice daily) plus ritonavir (100 mg orally twice daily) and
      Pegasys and Copegus (QUAD therapy), or 24 weeks of therapy with RO5024048 in combination
      with danoprevir plus ritonavir and Pegasys and Copegus (QUAD therapy). Anticipated time on
      study treatment is 24 or 26 weeks, with a treatment-free follow-up of 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained virologic response (defined as unquantifiable serum HCV RNA) 12 weeks after treatment (SVR-12)</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained virologic response 4 weeks after treatment (SVR-4)</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virologic response 24 weeks after treatment (SVR-24)</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum HCV RNA levels</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic response over time</measure>
    <time_frame>from baseline to 24 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between trough concentrations of RO4995855 and virologic response</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of direct-acting antiviral (DAA) resistance, including re-emergence of protease inhibitor resistant virus</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>1000 mg 24 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg 26 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1500 mg 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1500 mg 26 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5024048</intervention_name>
    <description>1500 mg po bid, 24 or 26 weeks</description>
    <arm_group_label>1500 mg 24 weeks</arm_group_label>
    <arm_group_label>1500 mg 26 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5024048</intervention_name>
    <description>1000 mg po bid, 24 or 26 weeks</description>
    <arm_group_label>1000 mg 24 weeks</arm_group_label>
    <arm_group_label>1000 mg 26 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26</description>
    <arm_group_label>1000 mg 24 weeks</arm_group_label>
    <arm_group_label>1000 mg 26 weeks</arm_group_label>
    <arm_group_label>1500 mg 24 weeks</arm_group_label>
    <arm_group_label>1500 mg 26 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 mcg sc qw, 24 or 26 weeks</description>
    <arm_group_label>1000 mg 24 weeks</arm_group_label>
    <arm_group_label>1000 mg 26 weeks</arm_group_label>
    <arm_group_label>1500 mg 24 weeks</arm_group_label>
    <arm_group_label>1500 mg 26 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin [Copegus]</intervention_name>
    <description>1000 mg or 1200 mg po daily, 24 or 26 weeks</description>
    <arm_group_label>1000 mg 24 weeks</arm_group_label>
    <arm_group_label>1000 mg 26 weeks</arm_group_label>
    <arm_group_label>1500 mg 24 weeks</arm_group_label>
    <arm_group_label>1500 mg 26 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26</description>
    <arm_group_label>1000 mg 26 weeks</arm_group_label>
    <arm_group_label>1500 mg 24 weeks</arm_group_label>
    <arm_group_label>1500 mg 26 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Hepatitis C genotype 1 infection

          -  Serum HCV quantifiable by Roche COBAS TaqMan HCV Test v2.0

          -  Liver biopsy (within 24 months) or Fibroscan (within 12 months) before first
             administration of study drug consistent with chronic hepatitis C and demonstrating
             absence of liver cirrhosis

          -  Documented failed prior treatment with protease inhibitor (evidenced by viral
             breakthrough or partial response while on treatment or relapse after treatment),
             including documentation on treatment with other direct-acting antiviral agents and
             other HCV antiviral treatment

          -  Patients must have discontinued prior HCV treatment at least 24 weeks prior to first
             dose of study drug in this trial

        Exclusion Criteria:

          -  Infection with any HCV genotype other than genotype 1

          -  Evidence of any variants associated with protease inhibitor resistance at screening

          -  Body mass index (BMI) &lt;18 or &gt;/=36 kg/m2

          -  Positive for hepatitis A or hepatitis B infection

          -  Use of any systemic antiviral therapy with perceived activity against HCV &lt;/=1 month
             prior to first dose of study drug

          -  History or evidence of a medical condition associated with chronic liver disease
             other than chronic hepatitis C

          -  Pregnant or breastfeeding women

          -  Males with female partners who are pregnant

          -  History of immunologically mediated disease; patients with rheumatoid arthritis
             requiring only intermittent non-steroidal anti-inflammatory medications or with
             celiac disease will be allowed

          -  History or evidence of decompensated liver disease

          -  History or evidence of renal disease; patients with history of nephrolithiasis will
             be allowed

          -  Uncontrolled Type 1 or 2 diabetes

          -  History or evidence of chronic pulmonary disease associated with functional
             limitation

          -  History of severe cardiac disease History of any neoplastic disease within the last 5
             years, except for localized or in situ carcinoma of the skin (e.g. basal or squamous
             cell carcinoma)

          -  Evidence of excessive alcohol, drug or substance abuse (excluding marijuana use)
             within 1 year of the first dose of study drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 1, 2015</lastchanged_date>
  <firstreceived_date>April 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
